Stem Cell Transplant for High Risk Central Nervous System (CNS) Tumors
Ann & Robert H Lurie Children's Hospital of Chicago
The primary goal of this study is to determine if a stem cell transplant in patients with newly diagnosed high risk CNS tumors (glioblastoma multiforme [GBM], high grade astrocytoma, pineoblastoma, rhabdoid tumor, supratentorial primitive neuroectodermal tumor [PNET]) increases overall survival.
Condition or disease:Glioblastoma
Rhabdoid Tumor
Supratentorial Neoplasms
Procedure: high dose chemotherapy
Phase:Phase 2
Study design:
Study Type:Interventional
:high dose chemotherapy with stem cell rescue thiotepa, carboplatin & etoposide
Primary Purpose:Treatment
Masking:None (Open Label)
Arm group:
Experimental: high dose chemotherapy
Procedure: high dose chemotherapy
Group A: recurrent medulloblastoma, recurrent germ cell tumor Cytoxan treatment Stem cell autologous harvest Group B: GBM, high grade astrocytoma, rhabdoid tumors, pineoblastoma, or supratentorial PNET Carboplatin and Etoposide treatment Autologous stem cell harvest The preparatory regimen used for Stem Cell Rescue #1 will be Carboplatinum, VP-16 and Thiotepa. If the patient has recuperated his ANC to >1,000 within 50 days after Stem Cell Rescue #1, (sustained without G-CSF support) a neuroradiographic evaluation will be performed. If there is lack of progression, the patient will then proceed to Stem Cell Rescue # 2 with Cyclophosphamide and Melphalan, followed by stem cell rescue.
Eligibility Criteria:
Ages Eligible for Study:18 Months to 18 Months
Sexes Eligible for Study:All
Accepts Healthy Volunteers:Yes

Inclusion Criteria:

- Patient's age must be greater than (>) 18 months and less than or equal to (≤) 25 years at the time of diagnosis or recurrence.

- Neuroradiographic evidence of a recurrent posterior fossa medulloblastoma or recurrent CNS germ cell tumor.

- The presence of a histologically confirmed high grade astrocytoma, GBM, rhabdoid tumor, supratentorial PNET, or pineoblastoma either at the time of diagnosis or recurrence.

- Patients must be brought to state of minimum residual disease by surgical reduction and/or chemotherapy and/or radiation therapy or a combination of above prior to myeloablative chemotherapy and tandem stem cell rescue.

- Documentation of chemotherapy sensitivity is required for enrollment. Chemotherapy-sensitive tumors are defined as those tumors which have had a reduction of 50% after 2-4 cycles of chemotherapy (CTX or platinum). For patients with no evidence of disease post resection, continued complete remission after 2-4 cycles of chemotherapy defines chemosensitivity.

- Adequate physiologic function, defined as follows:

- creatinine clearance > 70 ml/minutes/1.73 m2.

- SGPT < 10 x normal and bilirubin < 10 mg/dl.

- Adequate complete blood count (CBC): hemoglobin > 10 gm/dl, absolute neutrophil count (ANC) > 1500/ul, and platelets > 100,000/ul.

- Informed consent. The patient and/or the patient's legally authorized guardian must acknowledge in writing that consent to become a study subject has been obtained, in accordance with institutional policies provided by the United States (U.S.) Department of Health and Human Services.

- Protocol approval. Approval for the use of this institution's Human Rights Committee must be obtained in accordance with the institutional assurance policies of the U. S. Department of Health and Human Services.

- Patients with high-risk medulloblastoma after initial surgery.

- To allow non-English speaking patients to participate in this study, bilingual health care services will be provided in the appropriate language.

Exclusion Criteria:

- Patients with brain stem glioma are ineligible.

Primary Outcome Measures
1. To determine if the use of sequential myeloablative chemotherapy with peripheral blood stem cell rescue will increase the overall survival rate in patients with newly diagnosed high risk CNS tumors [To end of study]
Secondary Outcome Measures
1. The overall survival and progression free survival in children with recurrent CNS malignancies after obtaining a state of minimum residual disease with submyeloablative chemotherapy, surgery, and/or radiation. [To end of study]
2. To determine the progression free survival and overall survival using sequential myeloablative chemotherapy as compared to historical controls with single autologous stem cell rescue following myeloablative chemotherapy. [To end of study]
3. Determine the long term neurocognitive, endocrinologic, cardiopulmonary, and hematologic sequelae of sequential myeloablative chemotherapy and stem cell rescues in patients treated for high risk CNS and recurrent CNS tumors. [To end of study]
4. Determine the feasibility and utility of the myeloablative preparatory regimen of Carboplatinum, VP-16 and Thiotepa administered in an outpatient setting, and to determine the cost savings obtained via this strategy. [To end of study]
Discussion board
Collaboration tool especially designed for Life Science professionals.Drag-and-drop any entity to your messages.